key: cord-0430928-hperb4um
authors: Wang, Peng; Jin, Lin; Zhang, Min; Wu, Yunsong; Duan, Zilei; Chen, Wenwen; Wang, Chaoming; Liao, Zhiyi; Han, Jianbao; Guo, Yingqi; Guo, Yaqiong; Wang, Yaqing; Lai, Ren; Qin, Jianhua
title: SARS-CoV-2 causes human BBB injury and neuroinflammation indirectly in a linked organ chip platform
date: 2021-10-06
journal: bioRxiv
DOI: 10.1101/2021.10.05.463205
sha: 9f96bba8cd32a981f3ab1157033f11580acc3b92
doc_id: 430928
cord_uid: hperb4um

COVID-19 is a multi-system disease affecting many organs outside of the lungs, and patients generally develop varying degrees of neurological symptoms. Whereas, the pathogenesis underlying these neurological manifestations remains elusive. Although in vitro models and animal models are widely used in studies of SARS-CoV-2 infection, human organ models that can reflect the pathological alterations in a multi-organ context are still lacking. In this study, we propose a new strategy to probe the effects of SARS-CoV-2 on human brains in a linked alveolus-BBB organ chip platform. The new multi-organ platform allows to recapitulate the essential features of human alveolar-capillary barrier and blood-brain barrier in a microfluidic condition by co-culturing the organ-specific cells. The results reveal direct SARS-CoV-2 exposure has no obvious effects on BBB chip alone. While, infusion of endothelial medium from infected alveolus chips can cause BBB dysfunction and neuroinflammation on the linked chip platform, including brain endothelium disruption, glial cell activation and inflammatory cytokines release. These new findings suggest that SARS-CoV-2 could induce neuropathological alterations, which might not result from direct viral infection through hematogenous route, but rather likely from systemic inflammation following lung infection. This work provides a new strategy to study the virus-host interaction and neuropathology at an organ-organ context, which is not easily obtained by other in vitro models. This will facilitate to understand the neurological pathogenesis in SARS-CoV-2 and accelerate the development of new therapeutics. SUMMARY A linked human alveolus-BBB chip platform is established to explore the influences of SARS-CoV-2 on human brains in an organ-organ context. SARS-CoV-2 infection could induce BBB injury and neuroinflammation. The neuropathological changes are caused by SARS-CoV-2 indirectly, which might be mediated by systemic inflammation following lung infection, but probably not by direct viral neuroinvasion.

The coronavirus disease 2019 (COVID-19) is a multi-organ disease. Although the symptoms of COVID-19 are predominantly concentrated in human respiratory system, obvious organs dysfunction outside of the lungs are detected, including intestine, heart, kidney, liver and brain [1] [2] [3] [4] . Of note, accumulating clinical evidences showed 30-40% COVID-19 patients develop obvious neurological symptoms, such as headache, dizziness, psychosis, hypogeusia, hyposmia, cerebrovascular injury, seizures and encephalitis [5] [6] [7] [8] . In human brain, there is a highly selective blood-brain barrier (BBB), which controls the transport of nutrients and metabolites between the systemic circulation and the nervous system 9, 10 . Also, BBB functions as a protective barrier to prevent toxins and pathogens (including virus) from accessing the brain parenchyma. In some brain infectious diseases, neurotropic viruses can infect and disrupt BBB, and further invade human brain through the hematogenous route, such as HSV-1 and Zika virus [11] [12] [13] . However, whether SARS-CoV-2 can cross BBB to invade brain through the similar route remains elusive.

In the past year, great efforts have been made to investigate the influences of SARS-CoV-2 on brains. By examining autopsy samples from COVID-19 patients, several pathological studies revealed cerebral injuries in patients' brains, such as cerebrovascular damage and glial activation 14, 15 . Some studies using animal models, reported SARS-CoV-2 can be detected in brains after intranasal administration of virus, indicating potential neuroinvasion of SARS-CoV-2 [16] [17] [18] . As a new type of in vitro model, brain organoids contain multiple cell types and have been widely used in studies of the SARS-CoV-2 neurotropism, showing different susceptibility of various brain cells for the viral infection, including neurons, neural progenitor cells and astrocytes [19] [20] [21] [22] [23] [24] . However, some limitations constrain interpretations of these studies. As for autopsy brain tissues, limited availability of samples from COVID-19 patients and variability in patient presentation restricts their large-scale application 14, 15 . Classic animal models, such as rodents, are different from humans in physiological structure, and are limited in accurately recapitulating neuropathological changes of COVID-19 in humans 25, 26 . Regarding brain organoids, functional brain barriers and immune cells are absent, which makes it difficult to accurately recapitulate viral exposure and host immune responses in a physiological state. Especially, given that COVID-19 is a multi-organ disease, and damaged organs are closely associated during disease pathogenesis. Human organ models that can reflect pathological changes at systematic level is still lacking. Microfluidic organ chip models, emerging as in vitro microphysiological systems, possess the potential to recreate functional units from the native human organs or tissues. It can resemble the organ physiology in a human-relevant manner by mimicking the in vivo-like cellular microenvironment factors, such as cell-cell interactions and mechanical fluid flow. This technology has been developed to create a variety of organ models, such as the lung, liver, heart and BBB 10, [27] [28] [29] [30] [31] [32] [33] , holding great potential in disease modeling and drug testing. More recently, several organ chips have been leveraged to study host responses to SARS-CoV-2 infection and assess the antiviral effect of candidate drugs [34] [35] [36] [37] [38] [39] .

In this study, we proposed a new strategy to create a linked alveolus-BBB chip platform that allows to explore the effects of SARS-CoV-2 infection on human BBB in a multi-organ context. The multiorgan chip platform was created by linking an alveolus chip and BBB chip via fluidic control. Human peripheral blood immune cells were introduced into the multi-organ platform to simulate the cytokine storm following SARS-CoV-2-induced lung infection. Our study showed, direct SARS-CoV-2 exposure had no visible effects on BBB chip alone. While, SARS-CoV-2 induced BBB injury and inflammation indirectly following the systematic inflammation caused by lung infection on the linked chip platform. Collectively, our findings provide a possible explanation for pathogenesis underlying SARS-CoV-2-induced neurological symptoms, which does not result from direct viral infection through hematogenous route, but rather likely from systemic inflammation following lung infection.

Establishing a linked human alveolus-BBB chip platform for studies of viral infection COVID-19 is a multi-organ disease. Although lung is the major target organ for SARS-CoV-2, obvious neurological symptoms can be diagnosed in a large population of COVID-19 patients ( Figure 1A ). In order to probe the effects of SARS-CoV-2 infection on human brains in an organ-organ context, we plan to establish a linked human alveolus-BBB organ chip model system that enables to recapitulate the essential features of human alveolar-capillary barrier and blood-brain barrier in a physiologically relevant manner ( Figure 1B ). The human alveolus chip consisted of an upper epithelial channel and a lower vascular channel separated by a porous polyethylene terephthalate (PET) membrane (10 μm thick, 2 μm diameter). The alveolar-capillary barrier interface was established by co-culturing human alveolar epithelial cells (HPAEpiC) and human pulmonary microvascular endothelial cells (HULEC-5a) on the porous membrane (precoated with fibronectin) under microfluidic condition (100 μL/h) ( Figure 1C , D) 38 .

In human brain, brain microvascular endothelial cells (BMECs) are the primary anatomical component of the BBB and line the brain capillaries. They work in concert with basement membrane, perivascular astrocytes and pericytes, as well as neighboring neurons and microglia to form the neurovascular unit ( Figure 1E ) 10, [40] [41] [42] . To reconstitute the human BBB in vitro, we fabricated a microfluidic BBB chip, which consisted of an upper vascular channel and a parallel CNS channel separated by the porous PET membrane. Human brain microvascular endothelial cells (HBMEC) and human astrocytes (HA) were seeded on the opposite sides of porous membrane, mimicking the BBB interface in vivo, and the human microglial cells (HMC3) were cultured on the lower side of CNS channel. Both channels were perfused at a flow velocity of 100 μL/h for 3 days. Side view of confocal microscopic images revealed an intact tissue interface was formed on the porous membrane identified by VE-cadherin (adherens junction protein) in brain endothelial cells and GFAP (astrocytic marker) in astrocytes ( Figure 1F ), and a microglial layer (IBA1) was formed on the bottom side of CNS channel ( Figure 1G ). In brain endothelium, well developed adherens junctions (VE-cadherin) and tight junctions (ZO-1) were formed ( Figure 1H ). As for glial cells, obvious astrocyte markers (GFAP, S100β) and microglial markers (IBA1, CD11b) were detected on the astrocytic layer ( Figure 1I ) and microglial layer ( Figure 1J ), respectively. These results reveal the integrity of BBB interface was formed under the microfluidic condition.

In order to evaluate the viral invasiveness to human brain via infecting BBB, we conducted direct SARS-CoV-2 exposure test on individual BBB chip. The individual alveolus chip was infected with SARS-CoV-2 (MOI=1) in parallel as a positive control. For SARS-CoV-2 exposure test on BBB chip, we chose a MOI (MOI=1) that is much higher than physiological amount of SARS-CoV-2 exposure in peripheral blood for human brains. Initially, the expression of ACE2 and TMPRSS2 in cells which SARS-CoV-2 utilizes for cellular entry, was determined by Western blot. It appeared both proteins were expressed most highly in HPAEpiC cells (human alveolar epithelial type II cells-derived cell line), followed by two vascular endothelial cell lines (HULEC-5a, HBMEC) and glial cell lines (HA, HMC3) ( Figure 2A ). This was consistent with scRNA-seq analysis that ACE2 and TMPRSS2 are specifically highly co-expressed in human alveolar epithelial type II cells 43, 44 .

Three days post-infection, obvious infection and replication of SARS-CoV-2 was detected on the individual alveolus chip identified by viral Spike protein ( Figure 2B) , which was consistent with our previous study 38 . However, no obvious SARS-CoV-2 infection was detected on the individual BBB chip ( Figure 2C ). No visible changes in BBB permeability were observed following direct viral exposure either ( Figure 2D ). In brain endothelial cells, adherent junctions visualized by VE-cadherin were well preserved in the infected chip ( Figure 2E ). In the lower CNS channel of the infected chip, no viral infection and cell morphological changes were observed in both astrocytes and microglia as well ( Figure 2F , G).

To exclude the possibility that SARS-CoV-2 replication in BBB is very low and below the limits of detection by immunofluorescence, culture mediums of infected BBB chips were analyzed by qRT-PCR for viral RNA detection, which is a more sensitive method. The result showed ( Figure 2H ), viral loads of infected BBB chips were much lower than those of infected alveolus chips, indicating BBB is less permissive to SARS-CoV-2 direct infection, and the probability of direct neuroinvasion via BBB is low.

As direct viral exposure of SARS-CoV-2 had no visible effects on BBB chip alone, we then assumed neuropathological changes may be caused by the systematic inflammation following lung infection in an indirect manner.

To verify the hypothesis, we initially collected endothelial medium from the mock-or SARS-CoV-2 infected human alveolus chips (MOI=1), and then utilized it as conditional medium to treat BBB chips. Here, we chose influenza H1N1 virus (PR8 strain), as a reference in parallel (MOI=1) (Supplementary Figure 1A) . To test whether SARS-CoV-2 infection can induce a cytokine storm that commonly happens in severe COVID-19 cases, cytokines in culture supernatants of alveolus chips were detected 4 days after infection. The results showed 10 cytokines (including IFN-α2, IL-2, IFN-γ, IL-7, IL-1RA, IL-8, TNF-α, CXCL10, CCL3 and IL-10) were significantly released in the epithelial channels of SARS-CoV-2-infected alveolus chip (Supplementary Figure 1B) . Notably, although no obvious SARS-CoV-2 replication in the pulmonary endothelium ( Figure 2B ), obvious cytokines release (including IL-7, CXCL10, CCL3 and IL-10) was still detected in the endothelial channel (Supplementary Figure 1B Figure 1B) .

Then, the collected pulmonary endothelial medium was diluted with twice volume of fresh endothelial medium, and infused it into the vascular channel of BBB chips for continued culture. 4 days later, permeability assay showed infusion of endothelial medium from SARS-CoV-2-infected human alveolus chips induced a significant increase in BBB permeability, with a less increase in H1N1 virus group ( Figure 3A ).

As brain microvascular endothelial cells are the core anatomical component of BBB, tight junctions and adherens junctions play critical roles in keeping adjacent endothelial cells close together and preventing paracellular diffusion. We then detected the tight junctions and adherens junction following conditional medium treatment, and the results showed endothelial tight junctions and adherens junctions were severely disrupted, as indicated by altered ZO-1 and VE-cadherin organization, with a lesser change in H1N1 virus group ( Figure 3B ). Also, the endothelial cell density showed an obvious decrease in SARS-CoV-2 group ( Figure 3C ).

To monitor the conditions of astrocytes and microglia following conditional medium treatment, glial cells were examined by staining with cell-specific markers. Confocal microscopic analysis showed, both astrocytic markers (GFAP, S100β) ( Figure 3D ) and microglial markers (IBA1 and CD11b) ( Figure   3E ) were significantly up-regulated in SARS-CoV-2 group, while without obvious changes in H1N1 virus group. Intriguingly, in SARS-CoV-2 group, we noticed many microglia were distributed in cluster, resembling the focal microglial activation in vivo characterized by microglial nodules 14 . Besides, many lamellipodia (enlarged area in Figure 3E ) were observed in the microglia of SARS-CoV-2 group, and similar phenomenon of activated microglia were also reported in previous studies 45,46 . Consistently, the mRNA level of GFAP, S100β, IBA1 and CD11b were all specifically up-regulated in SARS-CoV-2 group by qRT-PCR analysis ( Figure 3F ). Besides, cytokine assay showed 10 cytokines (including IL-6, MCP-1, G-CSF, IL-2, IL-7, IL-1RA, IL-8, TNF-α, CCL3 and IL-10) were significantly released by the glial cells (CNS channel) in SARS-CoV-2 group ( Figure 3G ).

Since astrocytes and microglia were activated following pulmonary SARS-CoV-2 infection, we then investigated whether the activated glial cells were involved in the BBB damage, especially the brain endothelium disruption. Here, we ablated the astrocytes or microglia from the BBB chip, and examined their influences on brain endothelium following SARS-CoV-2 infection. As Figure 4A showed, 4 days after infusion of endothelial medium from SARS-CoV-2-infected alveolus chip, astrocytes or microglia ablation couldn't restore the normal cell periphery distribution of VE-cadherin and ZO-1. However, astrocytes ablation partially ameliorated the brain endothelial cell detachment from the porous membrane, while microglia ablation showed a weaker rescue effect ( Figure 4A , B). These results suggested, activated glial cells, especially activated astrocytes, exacerbated brain endothelial damage following SARS-CoV-2 infection on the linked chip platform. As the resident immune cells of nervous system, microglia play vital roles in the maintenance of brain homeostasis, and responses to injury or infection. Upon activation, microglia can dynamically change their status into M1 phenotype (proinflammatory) or M2 phenotype (anti-inflammatory), a process termed as polarization 47, 48 . To define the status of microglia during BBB damage, we examined the marker expressions of M1 or M2 microglia by staining F4/80 and CD206, respectively. A significant increase in F4/80 + cells (M1 marker) were observed in SARS-CoV-2 group, with no obvious change for CD206 + cells (M2 marker) ( Figure 4C , D), which indicated SARS-CoV-2 infection promoted M1 microglial polarization and induced neuroinflammation.

In addition to glial cells, peripheral immune cells may also participate in the BBB injury. To evaluate their roles, endothelial medium from SARS-CoV-2-infected alveolus chips containing ~1×10 5 PBMCs (pre-stained with Cell Tracker Red dye) were infused into the vascular channel of BBB chips, and 2 days later, the recruitment of peripheral immune was assessed by the PBMCs binding to the brain endothelium. The results showed, conditional medium treatment only leaded to a slight increase of PBMCs attachment on endothelium in the early stage of BBB injury (P value>0.05; Figure 4E , F).

All these findings indicated, SARS-CoV-2 could induce BBB injury and glial cell activation indirectly, which may be mediated by systematic inflammation after lung infection. Once the glial cells were activated, they exacerbated brain endothelial injury in turn and induced more severe inflammation.

COVID-19 is a systematic disease with multi-organ symptoms, and neurological symptoms are common in a large population of patients. In this study, we proposed a new strategy to probe the effects of SARS-CoV-2 infection on human brains in a linked chip platform. This linked chip platform was established by combining a human alveolar chip with a human BBB chip, and enabled to recapitulate the basic features of alveolar-capillary barrier and blood-brain barrier in vivo. Our results revealed, direct SARS-CoV-2 exposure to vascular side had no visible effects on the BBB chip alone, while it can lead to disrupted BBB and neuroinflammation following lung infection indirectly on the linked chip platform. These new findings suggested the neurological alterations in COVID-19 may not be caused by direct viral neuroinvasion, but rather likely are the consequences of systematic inflammation following lung infection. The pathological changes of central nervous system in COVID-19 patients have raised great concern.

Many studies uncovered neurological changes by examining autopsy brain samples from COVID-19 patients, and some of our findings are consistent with these pathological reports. A study reported, cerebral injuries, such as hypoxic/ischemic damage, hemorrhage and glial activation, can be detected in COVID-19 brain samples, whereas RNAscope and immunocytochemistry failed to detect SARS-CoV-2 14 . Even though qRT-PCR examination showed low or trace levels of viral RNA in some COVID-19 brains, the levels of detectable virus were not associated with the severity of neuropathological alterations 14, 15 . Similarly, a recent study of single-nucleus transcriptomes revealed no molecular traces of virus in the frontal cortex and choroid plexus samples of COVID-19 patients either 49 . All these findings indicated, the direct viral neuroinvasion may not be the prerequisite for the neurological manifestations of COVID-19. Notably, some pathological responses detected in our organ chip model, such as activated astrocytes with high degree of GFAP expression and activated microglia distributed in microglial nodules, were reminiscent of the similar phenomenon in brain tissues of COVID-19 patients 14, 15 , which verified the feasibility of our model in recapitulating neurological alterations in patients.

In human, BBB functions as a protective interface, prevents toxins and pathogens (including virus) from accessing the brain parenchyma. In regard to the viral neuroinvasion, several organoid models have been utilized to investigate the SARS-CoV-2 neurotropism and viral entry route to human brains [19] [20] [21] [22] [23] [24] , however, some limitations constrain interpretation of these studies. As these brain organoids have not realized vascularization and lack a functional BBB interface, making it difficult to accurately recapitulate the viral exposure in physiological state. Besides, no immune cells (such as peripheral blood immune cells, microglial cells) were present in these brain organoids, which made it unsuitable to evaluate the host immune responses and the impacts of systematic inflammation on brain following SARS-CoV-2 infection.

Compared with other in vitro models, the major advantage of this platform is the capability to introduce various of cell types or tissues according to research needs, such as immune cells, tissue interfaces and vasculatures. As for COVID-19, although immune cells and vascular endothelial cells are not the primary attack targets for virus, they contribute a lot to disease progression and some lifethreatening complications, such as inflammatory responses, systemic vasculitis and venous thromboembolism et al. [50] [51] [52] . In this model system, peripheral blood immune cells were introduced into the alveolus chips, and robust inflammatory cytokines release was detected following SARS-CoV-2 infection, mimicking the cytokine storms commonly happening in severe COVID-19

cases. In our previous study on human alveolus chip model alone, the inclusion of peripheral immune cells significantly exacerbated the cytokines release and SARS-CoV-2-induced alveolar injury 38 . Regarding vascular endothelial cells, our studies revealed exposure to the pulmonary endothelial medium containing pro-inflammatory cytokines triggered a second release of cytokines and chemokines in the vascular channel of BBB chips (Supplementary Figure 2) . Through this amplification loop of inflammatory response, the brain endothelium constituted a significant source of inflammatory cytokines in human brains, such as IL-1, IL-6 and TNF-α that characterize the cytokine storm in COVID-19. All these findings indicated immune cells and endothelial cells are two major characters involved in COVID-19 pathogenesis.

It's worth noting that, in the study we only discussed one potential entry route of SARS-CoV-2 to human brains actually. In addition to BBB, there is another barrier system in human 

Cell culture Vero E6 cells were obtained from American Type Culture Collection (ATCC; no. 1586), and maintained in MEM medium (Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% Penicillin/Streptomycin (P/S). HPAEpiC were purchased form ScienCell Corporation (no. 3200), and maintained in RPMI 1640 medium (Gibco) supplemented with 10% FBS and 1% P/S. HULEC-5a cells were purchased from Procell Corporation (no. CL-0565; introduced from ATCC Company), and maintained in a special pulmonary endothelial medium (Procell Corporation, no. CM-0565). HBMEC cells were purchased from ScienCell Corporation (no. 1000), and maintained in ECM medium (ScienCell; no. 1001) supplemented with 10% FBS, 1% ECGS and 1% P/S. HA cells were a kind gift from Dr. Dan Liu's lab (Huaqiao University), which was purchased from ScienCell Corporation (no. 1800), and maintained in AM medium (ScienCell; no. 1801) supplemented with 2% FBS, 1% AGS and 1% P/S. HMC3 cells were purchased from Procell Corporation (no. CL-0620), and maintained in MEM medium containing NEAA (Procell; no. MP150410) supplemented with 10% FBS and 1% P/S. Human peripheral blood mononuclear cells (PBMCs) were isolated from fresh human peripheral blood using Ficoll (GE Healthcare) density gradient centrifugation, and were cultured in RPMI 1640 medium containing 10% FBS, 1% P/S and 50 IU/mL IL-2. All cells were cultured at 37 °C in a humidified atmosphere of 5% CO2.

The human BBB chip device consists of an upper and lower layer fabricated by casting Polydimethylsiloxane (PDMS) pre-polymer on molds prepared using conventional soft lithography procedures. 10:1 (wt/wt) PDMS base to curing agent (184 Silicone Elastomer, Dow Corning Corp) was polymerized to produce molded device with channels by thermal curing at 80 °C for 45 min. The top channel (1.5 mm wide × 0.2 mm high) and bottom channel (1.5 mm wide × 0.2 mm high) are used to form the vascular lumen and the CNS layer, respectively. The overlapping area of upper and lower channels is 26.2985 mm 2 . The two channels are separated by a thin (10 μm thick) and porous (2 μm diameter) PET membrane to construct the tissue-tissue interface. Before seeding cells on the chips, the chips were sterilized by ultraviolet irradiation overnight and then were pre-coated with 50 μg/mL fibronectin at 37 °C for 24 hours. After cell attachment, constant media flows (100 l/h) were applied in both the upper and bottom layers using a LongerPump. The cells were cultured for 3 days to form confluent blood-brain barrier interface.

All the chips were maintained in an incubator with 5% CO2 at 37°C . 

Firstly, 100 μL fresh pulmonary endothelial medium containing ~1×10 5 PBMCs were infused in the lower vascular channel. Then, SARS-CoV-2 or H1N1 virus (MOI=1) was inoculated in the upper alveolar channels. One hours later, the upper alveolar channels were washed twice with PBS, and then 100 μL fresh RPMI 1640 medium was infused into the upper alveolar channels. Every two days (Day 2, 4, 6 post-infection), endothelial medium (conditional medium) was collected, centrifuged (10,000 g; 10 min) and stored as at -80 °C. 100 μL fresh pulmonary endothelial medium containing ~1×10 5

PBMCs and 100 μL fresh RPMI 1640 medium was infused into the lower and upper channels respectively for continued culture.

Pulmonary endothelial culture supernatants from the infected alveolus chips (Mock, SARS-CoV-2 or H1N1 virus-infected) were diluted with twice volume of fresh ECM medium. Every two days, 100 μL diluted conditional medium and 100 μL fresh glial cell medium (HA cell medium : HMC3 cell medium=1:1) was infused into the upper and lower channels of BBB chips, respectively for continued culture (4 days).

Cells were washed twice with PBS through the upper and lower channels and fixed with 4% PFA overnight. The fixed cells were permeabilized and blocked with PBST (0.2% Triton X-100 in PBS) buffer containing 5% normal goat serum for 30 min at room temperature. Antibodies were diluted with PBST buffer and infused into the upper and lower channels, respectively. Cells were stained with the primary antibodies at 4 °C overnight, and with the secondary antibodies at room temperature for 1 h.

After counterstained with DAPI, chips were disassembled, and porous membrane and lower channel were mounted on slides respectively. All images were acquired using a Carl Zeiss LSM880 confocal fluorescent microscope system. Image processing was done using ImageJ software (NIH). according to the manufacturer's instructions.

Protein samples were separated on 10% SDS-PAGE and then transferred onto 0.2 μm nitrocellulose membranes (GE Amersham). After being blocked with 5% non-fat powdered milk in TBST buffer containing 0.05% Tween-20, the membranes were probed with the primary antibodies at 4 °C overnight.

The membranes were then probed with corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies at room temperature for 1 h at room temperature. Protein bands were detected by Prime Western Blotting Detection Reagent (GE life).

Data were collected by Excel (Microsoft) software. The GraphPad Prism 6 software was used for data statistical analysis. All experiments were performed at least three times. During the experiment and assessing the outcome, the investigators were blinded to the group allocation. Differences between two groups were analyzed using unpaired Student's t test. Multiple group comparisons were performed using a one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test. The bar graphs with error bars represent mean ± standard error of the mean (SEM). Significance is indicated by asterisks: *, P < 0.05; **, P < 0.01; ***, P < 0.001.

diagram of human body exposed to SARS-CoV-2. ( 

COVID-19 can affect the heart

Gastrointestinal and liver manifestations in patients with COVID-19

COVID-19 and acute kidney injury

Central nervous system manifestations of COVID-19: A systematic review

Can SARS-CoV-2 infect the central nervous system via the olfactory bulb or the blood-brain barrier?

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

In vitro modeling of the neurovascular unit: advances in the field

Advances in Microfluidic Blood-Brain Barrier (BBB) Models

Astrocyte-and Neuron-Derived CXCL1 Drives Neutrophil Transmigration and Blood-Brain Barrier Permeability in Viral Encephalitis

Herpes Simplex Virus 1-Induced Blood-Brain Barrier Damage Involves Apoptosis Associated With GM130-Mediated Golgi Stress

Zika Virus Infection Promotes Local Inflammation, Cell Adhesion Molecule Upregulation, and Leukocyte Recruitment at the Blood-Brain Barrier

COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

The olfactory route is a potential way for SARS-CoV-2 to invade the central nervous system of rhesus monkeys

Neuroinvasion of SARS-CoV-2 in human and mouse brain

SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration

SARS-CoV-2 infects human neural progenitor cells and brain organoids

SARS-CoV-2 targets neurons of 3D human brain organoids

Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2

SARS-CoV-2 targets glial cells in human cortical organoids

SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids

Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium

K18-hACE2 mice develop respiratory disease resembling severe COVID-19

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

Reconstituting organ-level lung functions on a chip

Human iPSC-Derived Blood-Brain Barrier Chips Enable Disease Modeling and Personalized Medicine Applications

Microengineered human blood-brain barrier platform for understanding nanoparticle transport mechanisms

A liver-on-a-chip platform with bioprinted hepatic spheroids

A Bioprinted Liver-on-a-Chip for Drug Screening Applications

Microfluidic heart on a chip for higher throughput pharmacological studies

Generation of functional cardiac microtissues in a beating heart-on-a-chip

SARS-CoV-2 causes severe epithelial inflammation and barrier dysfunction

SARS-CoV-2 induced intestinal responses with a biomimetic human gut-on-chip

A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics

Rapid endotheliitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-chip model

Biomimetic Human Disease Model of SARS-CoV-2 Induced Lung Injury and Immune Responses on Organ Chip System

The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier

The blood-brain barrier: an overview: structure, regulation, and clinical implications

Development, maintenance and disruption of the blood-brain barrier

Astrocyte-endothelial interactions at the blood-brain barrier

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Nonpsychotropic cannabinoid receptors regulate microglial cell migration

Late endosomes promote microglia migration via cytosolic translocation of immature protease cathD

Modulators of microglial activation and polarization after intracerebral haemorrhage

Microglial M1/M2 polarization and metabolic states

Dysregulation of brain and choroid plexus cell types in severe COVID-19

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection

COVID-19 and the immune system

Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in health and disease

Development and functions of the choroid plexuscerebrospinal fluid system

Neurologic Features in Severe SARS-CoV-2 Infection

Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid

The authors declare that they have no conflict of interest.